WORCESTER, Mass., Dec. 15, 2010 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board: GNBT) announced today that it has received a new patent for its buccal drug delivery platform technologies. The Canadian Intellectual Property Office has granted to Generex Canadian Patent No. 2,354,148, a patent titled Aerosol Formulations for Buccal and Pulmonary Application.
This new patent increases the number of issued patents related to the Company's buccal drug delivery platform technologies to 162. A total of 101 patent applications in the field remain pending.
"We continue to augment the breadth and depth of the intellectual property protection for our drug delivery platform," observed Rose C. Perri, the Company's Chief Operating Officer, "as we continue to pursue the platform's commercialization opportunities for insulin and other active pharmaceutical ingredients."
About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMistTM device. The Company's buccal insulin spray product, Generex Oral-lynTM, which has been approved in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.